期刊
REPRODUCTIVE BIOMEDICINE ONLINE
卷 43, 期 4, 页码 727-737出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.rbmo.2021.07.002
关键词
Biomarker; Diagnosis; LC-MS; MS; Metabolomics; Peritoneal endometriosis
资金
- National Research Foundation Singapore under its National Medical Research Council Centre Grant Program [NMRC/CG/M003/2017]
- Duke-NUS Office of Academic Medicine (Clinical and Translational Research in Endometriosis)
- SingHealth Foundation Research Grant [SHF/FG671P/2017]
- Singapore's Ministry of Health's National Medical Research Council [CSA-SI-008-2016]
The study identified potential biomarkers for peritoneal endometriosis in peritoneal fluid and serum using metabolomics analysis. Phenylalanyl-isoleucine showed promising discriminatory performance in distinguishing peritoneal endometriosis from controls, particularly in the proliferative phase. Further research is needed to validate these findings and assess the clinical utility of phenylalanyl-isoleucine as a diagnostic biomarker for peritoneal endometriosis.
Research question: What are the potential biomarkers for peritoneal endometriosis in peritoneal fluid and serum? Design: Case-control studies composed of independent discovery and validation sets were conducted. In the discovery set, untargeted liquid chromatography-mass spectrometry (LC-MS/MS) metabolomics, multivariable and univariable analyses were conducted to generate global metabolomic profiles of peritoneal fluid for endometriosis and to identify potential metabolites that could distinguish peritoneal endometriosis (n = 10) from controls (n = 31). The identified metabolites from the discovery set were validated in independent peritoneal fluid (n =19 peritoneal endometriosis and n = 20 controls) and serum samples (n = 16 peritoneal endometriosis and n = 19 controls) using targeted metabolomics. The area under the receiver-operating characteristics curve (AUC) analysis was used to evaluate the diagnostic performance of peritoneal endometriosis metabolites. Results: In the discovery set, peritoneal fluid phosphatidylcholine (34:3) and phenylalanyl-isoleucine were significantly increased in peritoneal endometriosis groups compared with control groups, with AUC 0.77 (95% CI 0.61 to 0.92; P = 0.018) and AUC 0.98 (95% CI 0.95 to 1.02; P < 0.001), respectively. In the validation set, phenylalanyl-isoleucine retained discriminatory performance to distinguish peritoneal endometriosis from controls in both peritoneal fluid (AUC 0.77, 95% CI 0.61 to 0.92; P = 0.006) and serum samples (AUC 0.81, 95% CI 0.64 to 0.99; P = 0.004), with notably stronger discrimination between peritoneal endometriosis and controls in proliferative phase. Conclusion: Our preliminary results propose phenylalanyl-isoleucine as a potential biomarker of peritoneal endometriosis, which may be used as a minimally invasive diagnostic biomarker of peritoneal endometriosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据